Hepatic Venous Pressure Gradient: Measurement and Pitfalls.
Beta-blockers invasive
Catheterization
Cirrhosis
HVPG
Portal hypertension
Portal pressure monitoring
Journal
Clinics in liver disease
ISSN: 1557-8224
Titre abrégé: Clin Liver Dis
Pays: United States
ID NLM: 9710002
Informations de publication
Date de publication:
Aug 2024
Aug 2024
Historique:
medline:
1
7
2024
pubmed:
1
7
2024
entrez:
30
6
2024
Statut:
ppublish
Résumé
Measurement of hepatic venous pressure gradient (HVPG) effectively mirrors the severity of portal hypertension (PH) and offers valuable insights into prognosis of liver disease, including the risk of decompensation and mortality. Additionally, HVPG offers crucial information about treatment response to nonselective beta-blockers and other medications, with its utility demonstrated in clinical trials in patients with PH. Despite the widespread dissemination and validation of noninvasive tests, HVPG still holds a significant role in hepatology. Physicians treating patients with liver diseases should comprehend the HVPG measurement procedure, its applications, and how to interpret the results and potential pitfalls.
Identifiants
pubmed: 38945633
pii: S1089-3261(24)00034-5
doi: 10.1016/j.cld.2024.03.009
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
383-400Informations de copyright
Copyright © 2024 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Disclosure S.G. Rodrigues, M.G. Delgado, and G. Stirnimann have nothing to disclose. A. Berzigotti is a consultant for Boehringer-Ingelheim. J. Bosch is a consultant for AstraZeneca, Boehringer-Ingelheim, NovoNordisk, Resolution Therapeutics.